Upload
gunter-hennersdorf
View
3.262
Download
2
Embed Size (px)
DESCRIPTION
Citation preview
Congestive Heart Failure
3. Treatment
March 2013 ghennersdorf DGK ESC SES 1
Medical Science Tanzania Cardiology Lectures
Prof. Hennersdorf SES
General signs and symptoms
March 2013 ghennersdorf DGK ESC SES 2
Definition of Heart Failure CHF
• New York Heart Association (NYHA)– I no visible signs and symptoms– II signs and symptoms at high level exercise– III signs and symptoms at low level exercise– IV no physical exercise possible, bed rest
necessary
March 2013 ghennersdorf DGK ESC SES 3
Worldwide used as functional definition of CHF!
Treatment Goals
March 2013 ghennersdorf DGK ESC SES 4
IV
III
II
I
??
??
??
HTX option
Main treatment goalfor chronic disease
Main treatment goalfor acute disease
Therapeutic objectives
• Acute CHF– Treatment of life threat– Improvement of life quality
• Chronic CHF– Improvement of life quality– Reduction of Disability– Increase of longevity
March 2013 ghennersdorf DGK ESC SES 5
Adding life to years rather than years to life
Main approachVasodilation
Organ protectionVolume control
Therapeutic options
March 2013 ghennersdorf DGK ESC SES 6
Acute Heart Failure
Therapeutic options (ER, ICU)• Physical approach in cardiogenic pulmonary edema
– Oxygen delivery– Bed rest / upright position– Secure (central) venous line– Urinary catheter– Blood letting
• Drugs (iv administration)– Diuretics (short term, furosemide)– Digitalis (?; fast AF ?)– Thrombembolic prophylaxis (heparin; PTT necessary)
• Drugs orally (cave hypotension)– Nitroglycerine sublingually– Consider ACEI sublingually
March 2013 ghennersdorf DGK ESC SES 7
Therapeutic options (cardiogenic shock)
• Volume expansion under hemodynamic control– Pulmonary artery cath– Arterial pressure line
• Mechanical assistance: IABP• Cathlab: PCI• Surgery: revascularization• Drugs
– Catecholamines: Dopamin, Dobutamin– Phosphodiesterase (PDE)-Inhibitors: Amrinone, Milrinone (not
evidence based)– Thrombembolic prophylaxis: heparine (PTT)– Fast acting diuretics
• Acid base control• Electrolyte contol (potassium)
March 2013 ghennersdorf DGK ESC SES 8
Therapeutic options
March 2013 ghennersdorf DGK ESC SES 9
Chronic Heart Failure
Evidence
March 2013 ghennersdorf DGK ESC SES 10
Therapeutic challenge
March 2013 ghennersdorf DGK ESC SES 11
Systolic heart failure: mostly common in CHD and RHDDrugs and recommendations according to guidelines
Diastolic heart failure: mostly common in hypertensionLong term follow up dependent on treatment of underlying diseaseDrugs recommendations not yet established
Therapeutic options
• First line recommendation: Prevention– Prevention of CHD, Hypertension, valvular
disease, infections– Information, home care, transmission of simple
behavior rules:• Hygiene and clean water supply• Motion: physical activity, limited sport action• Nutrition: salt restriction• Refrain smoking
March 2013 ghennersdorf DGK ESC SES 12
Therapeutic options• Conservative
– RAS modification• ACE-I• AT1-receptor antagonists• Aldosterone antagonists (Eplerenone ®)
– beta-AR competition• Betablockers
– classical 3D options• Diuretics (fast acting, medium acting; cave potassium)• Diet• Digitalis (?) not first choice!
– Others: (Pulmonary artery Hypertension)• Bosentan • Sildenafil
March 2013 ghennersdorf DGK ESC SES 13
Avoid use of NSAIDs like COXIBs
ß-Blockade in CHF
March 2013 ghennersdorf DGK ESC SES 14
ß-Blockade in CHF
March 2013 ghennersdorf DGK ESC SES 15
ß-Blockade in CHF
March 2013 ghennersdorf DGK ESC SES 16
Muscle cell; contractilityNENEE
Muscle cell; contractility
NENENENEEEE
Muscle cell; contractility
NENENENEEEE
Betablockade: receptor recovery,function improves
AR Reduction
AR Recovery
Reduction of adrenergic receptors AR
ß-Blockade in CHF
March 2013 ghennersdorf DGK ESC SES 17
Recommended: ß1-selective drugs like metoprolol, bisoprolol+ vasodilatation: carvedilol, nevibolol
Therapeutic options. ACE-I
• Trials– CONSENSUS 1987 Captopril– SOLVD 1999 Enalapril– SAVE 1992 Captopril– VHEFT 1991 Enalapril/Hydralazin– CIBIS III 2005 Enalapril/Bisoprolol
March 2013 ghennersdorf DGK ESC SES 18
Demonstrate highly significant improvement of survival in different stages of heart failure (II –IV): Evidence Class A - IA
Dosage recommendations
March 2013 ghennersdorf DGK ESC SES 19
Dosage recommendations
March 2013 ghennersdorf DGK ESC SES 20
Improvement of HF in cardiac CXR
March 2013 ghennersdorf DGK ESC SES 21
before treatment after treatment
Therapeutic options
• Surgical– Heart transplantation, bridging– Cardiomyoplasty
• Resynchronizing pacemaker therapy (CRT)• Stem cell replacement
March 2013 ghennersdorf DGK ESC SES 22
Therapeutic options
• HTX– Surgically solved– Concomitant therapy problems (rejection) solved– Donor problems unsolved and will persist
March 2013 ghennersdorf DGK ESC SES 23
But: therapeutic choice for subsets of younger patients with severe symptoms mostly on
iv therapy and/or ICU care without chance to recover appropriately.
Bridging procedure desirable
Heart transplantation HTX
March 2013 ghennersdorf DGK ESC SES 24
Heart transplantation
March 2013 ghennersdorf DGK ESC SES 25
Heart transplantation
March 2013 ghennersdorf DGK ESC SES 26
3rd september 1967
original OR theatreGroote Schuur HospitalCape Town SAR
Christian Neethling Barnard
Artificial heart
March 2013 ghennersdorf DGK ESC SES 27
Heartmate® for bridging procedures
Survival after HTX
March 2013 ghennersdorf DGK ESC SES 28
Therapeutic options: cardiac resynchronization therapy CRT
March 2013 ghennersdorf DGK ESC SES 29
Therapeutic options
March 2013 ghennersdorf DGK ESC SES 30
Therapeutic options: resynchronization therapy
March 2013 ghennersdorf DGK ESC SES 31
Therapeutic options: stem cells
March 2013 ghennersdorf DGK ESC SES 32
Therapeutic challenge: home care
• Medication starts in the hospital• Medication continues in household enviroment, rural areas • Doctor‘s contacts rare• Patient‘s survey difficult.• Therefore: narrow control schedules concerning
– Nurse directed home care– Continuous medical education of both patient and personal
(nurses/doctors)– Outpatient visits– Establishing telemedical processes
March 2013 ghennersdorf DGK ESC SES 33
Therapeutic home care options• Home care (nurse driven)
– Scheduled visits on regular basis (nurse, AMO)– Visits following questionnaire– Data acquisition and transmission
(telemedicine?)• Severity of symptoms• Daily activities ability• Controls
– Medication– Weight (listing by patient)– Blood pressure– other
March 2013 ghennersdorf DGK ESC SES 34
CHF Questionnaire; example
March 2013 ghennersdorf DGK ESC SES 35
How do you feel since last visit? Scale of 10 ptsIn your opinion, are there main changes:
breathingweight gainUrinary outputpalpitation?
How do you think developed your personal daily activities (DAs)?
worsesamebetter
which kind of DAs is mostly impaired?homeleisureemployment
What about your medication:intake OK?complaints?self made changes?incompatibilty?wishes?
Suggestions?
Heart Network
March 2013 ghennersdorf DGK ESC SES 36
Patient
Hospital
Home Care
OPD
District Hospital
Dispensary
Heart Network: nurse
March 2013 ghennersdorf DGK ESC SES 37
+
Hospital
Nurse
home care
Heart Network: Internet
March 2013 ghennersdorf DGK ESC SES 38
Patient data file, database: EPF*Access by authorized personal throughout the country
*electronic patient file
Heart Network
• Telecardiology (telemedicine)– Electronic provision of data transmission– Generation of medical data in remote areas (rural)– Overcoming of doctors shortages – Secure transmission line– Targets:
• Hospital Centers• Home care physician• Home care nurse• Specialized medical call centers
March 2013 ghennersdorf DGK ESC SES 39
Heart Network
March 2013 ghennersdorf DGK ESC SES 40
• Telemedical patient kit – Smartphone with Apps (Skype)– Balance– ECG device– Blood pressure device– Glukose test kit– Finger tip pulse oxymeter– Questionnaire
The End
March 2013 ghennersdorf DGK ESC SES 41